China's top drug regulator said Friday that it approved Merck & Co.'s Molnupiravir for emergency use on Wednesday, as the country grapples with waves of infections after Beijing abruptly reversed its stringent Covid-19 restrictions earlier this month.

The National Medical Products Administration said it is requiring the approval holder to continue relevant research, complete conditional requirements and submit follow-up research results in a timely manner, according to a statement posted on its website Friday.

Write to Singapore Editors at singaporeeditors@dowjones.com

(END) Dow Jones Newswires

December 30, 2022 03:24 ET (08:24 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Merck (NYSE:MRK)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Merck Charts.
Merck (NYSE:MRK)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Merck Charts.